J. Zhuo

发表

Remission Rate and Functional Outcomes During a 6-Month Treatment With Osmotic-Release Oral-System Methylphenidate in Children With Attention-Deficit/Hyperactivity Disorder

Yufeng Wang, Yi Su, Haibo Li, 2015, Journal of clinical psychopharmacology.

Switching to paliperidone extended release in patients with schizophrenia dissatisfied with previous olanzapine treatment

T. Si, J. Zhuo, S. Cai, 2019, Medicine.

Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics

T. Si, Yu Feng, Lili Zhang, 2018, Neuropsychiatric disease and treatment.

Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study

M. Mathews, Huafang Li, Yan Li, 2018, Neuropsychiatric disease and treatment.

Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety

Jinan Wang, Xiufeng Xu, Z. Yao, 2018, Neuropsychiatric disease and treatment.

Efficacy and safety of escitalopram in treatment of severe depression in Chinese population

G. Wang, Y. Fang, T. Si, 2017, Metabolic Brain Disease.

Once-monthly injection of paliperidone palmitate in patients with recently diagnosed and chronic schizophrenia: a post-hoc comparison of efficacy and safety

T. Si, M. Mathews, Yu Feng, 2017, Expert opinion on pharmacotherapy.

Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study

Jingping Zhao, Xiufeng Xu, Yi Li, 2017, Neuropsychiatric disease and treatment.

An Open-label, Self-control, Prospective Study on Cognitive Function, Academic Performance, and Tolerability of Osmotic-release Oral System Methylphenidate in Children with Attention-deficit Hyperactivity Disorder

Yi Zheng, Rong Li, F. Jia, 2015, Chinese medical journal.

Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia

T. Si, Yu Feng, Lili Zhang, 2019, Neuropsychiatric disease and treatment.

NDT_A_191803 1685..1694

T. Si, Yu Feng, Lili Zhang, 2019 .

Long-term ef fi cacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia

T. Si, Yu Feng, Lili Zhang, 2019 .

Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence

T. Si, C. Correll, Yu Feng, 2018, Journal of psychopharmacology.

Paliperidone Palmitate Improves and Maintains Functioning in Asia–Pacific Patients with Schizophrenia

Hongyan Zhang, M. Mathews, Yu Feng, 2017, Advances in Therapy.

A post hoc analysis on hospitalization risk in Asian patients with schizophrenia switching to once-monthly paliperidone palmitate from oral antipsychotics

M. Mathews, Yu Feng, I. Turkoz, 2019, Expert opinion on pharmacotherapy.

Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication

Yunlong Tan, Ning Wang, Juan Li, 2017, Neuropsychiatric disease and treatment.

A Subgroup Analysis of Chinese Patients Switched to Paliperidone Palmitate One-Month Injectable by Prior Oral Antipsychotic Treatment

T. Si, X. Wang, C. Xu, 2015, Pharmacopsychiatry.

Impacts of early therapy response, interval to therapy interruption, and cumulative therapy interruption duration on outcome of ibrutinib therapy in relapsed/refractory chronic lymphocytic leukemia

R. Gale, Xiaojun Huang, Yu Feng, 2023, Annals of Hematology.

Association between symptom control and functional improvement in patients with acute schizophrenia: A post hoc analysis of an open-label, single-arm, multi-center study of paliperidone-extended release formulation

T. Si, Yu Feng, Lili Zhang, 2019, Psychiatry Research.